Literature DB >> 108675

Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.

B Ullman, L J Gudas, S M Clift, D W Martin.   

Abstract

The inherited deficiency of purine-nucleoside phosphorylase (PNPase; purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1) in humans is associated with a severe deficiency of the T lymphocytes of the immune system. Because of the unsatisfactory nature of previously described model systems, we have selected, cloned, and characterized a mutant mouse T cell lymphoma (S49) completely deficient in PNPase. Of the four substrates of PNPase, only deoxyguanosine at low concentrations is toxic to the PNPase-deficient (NSU-1) cells. In order to delineate the biochemical processes necessary for the sensitivity of the NSU-1 cells to deoxyguanosine, we have isolated a series of secondary mutants resistant to deoxyguanosine from the PNPase-deficient line. One of these mutants is defective in its ability to transport deoxyguanosine into the cell. A second type of mutant cannot phosphorylate the deoxyguanosine and is totally deficient in deoxycytidine kinase activity. A third type of mutant (NSU-1-dGuo-L) can both transport and phosphorylate deoxyguanosine and accumulates dGTP. However, unlike its parent, NSU-1-dGuo-L does not become depleted of dCTP and TTP when exposed to exogenous deoxyguanosine. This observation is accounted for by the fact that the reduction of CDP to dCDP by the ribonucleotide reductase (ribonucleoside-diphosphate reductase, 2'-deoxyribonucleoside-diphosphate:oxidized-thioredoxin 2'-oxidoreductase, EC 1.17.4.1) of NSU-1-dGuo-L cells is not normally sensitive to feedback inhibition by dGTP.Thus, in order to exert its toxicity deoxyguanosine must be transported into the cell, be phosphorylated by deoxycytidine kinase, and be accumulated as dGTP. By inhibiting ribonucleotide reductase, dGTP depletes the cell of dCTP and to some extent TTP, thus preventing the synthesis of DNA, a process necessary for any proliferation-dependent function of T cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108675      PMCID: PMC383191          DOI: 10.1073/pnas.76.3.1074

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Further studies on the effect of deoxyadenosine on the accumulation of deoxyadenosine triphosphate and inhibition of deoxyribonucleic acid synthesis in Ehrlich ascites tumor cells in vitro.

Authors:  H KLENOW
Journal:  Biochim Biophys Acta       Date:  1962-12-31

2.  Studies on a possible regulatory mechanism for the biosynthesis of deoxyribonucleic acid.

Authors:  P REICHARD; Z N CANELLAKIS; E S CANELLAKIS
Journal:  J Biol Chem       Date:  1961-09       Impact factor: 5.157

3.  Dependence of bone marrow cells on the liver for purine supply.

Authors:  L G LAJTHA; J R VANE
Journal:  Nature       Date:  1958-07-19       Impact factor: 49.962

4.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; A Cohen; D W Martin
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

6.  Lymphocyte ecto-5'-nucleotidase deficiency in agammaglobulinemia.

Authors:  N L Edwards; D B Magilavy; J T Cassidy; I H Fox
Journal:  Science       Date:  1978-08-18       Impact factor: 47.728

7.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

8.  Analysis of adenosine-mediated pyrimidine starvation using cultured wild-type and mutant mouse T-lymphoma cells.

Authors:  L J Gudas; A Cohen; B Ullman; D W Martin
Journal:  Somatic Cell Genet       Date:  1978-03

9.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

10.  Characterization of a cell culture model for the study of adenosine deaminase- and purine nucleoside phosphorylase-deficient immunologic disease.

Authors:  B Ullman; A Cohen; D W Martin
Journal:  Cell       Date:  1976-10       Impact factor: 41.582

View more
  39 in total

1.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 2.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

3.  Deoxycytidine deaminase-deficient Escherichia coli strains display acute sensitivity to cytidine, adenosine, and guanosine and increased sensitivity to a range of antibiotics, including vancomycin.

Authors:  Tina Manzhu Kang; Jessica Yuan; Alice Zhou; Casey Beppler; Jeffrey H Miller
Journal:  J Bacteriol       Date:  2014-03-14       Impact factor: 3.490

4.  Compartmentation of guanine nucleotide precursors for DNA synthesis.

Authors:  B T Nguyen; W Sadée
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

5.  B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.

Authors:  A Goday; H A Simmonds; G S Morris; L D Fairbanks
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

6.  Guanine ribonucleotide depletion in mammalian cells. A target of purine antimetabolites.

Authors:  B T Nguyen; M B Cohen; W Sadée
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization.

Authors:  S R Williams; J M Goddard; D W Martin
Journal:  Nucleic Acids Res       Date:  1984-07-25       Impact factor: 16.971

Review 8.  Metabolic defects in immunodeficiency diseases.

Authors:  A D Webster
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  Enzymes of purine metabolism in human peripheral lymphocyte subpopulations.

Authors:  M Massaia; D D Ma; T A Sylwestrowicz; N Tidman; G Price; G Janossy; A V Hoffbrand
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

10.  Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency.

Authors:  M R Aust; L G Andrews; M J Barrett; C J Norby-Slycord; M L Markert
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.